Diurnal is a clinical stage specialty pharmaceutical company focused on diseases of the endocrine system. It has two lead candidates – Infacort® and Chronocort® – in Phase III trials targeted at rare diseases with unmet medical need with which it aims to build a long-term ‘Adrenal Franchise’. The cortisol replacement market is for conditions that need life-long treatments, with a potential value of $3.5bn. Despite this, the market is characterised by few competitors, and Diurnal will target a network of specialist endocrinology centres in Europe and US by itself. Upcoming newsflow on trials and regulatory filings will draw attention to the stock.
Sign up for free to access
Get access to the latest equity research in real-time from 12 commissioned providers.
Get access to the latest equity research in real-time from 12 commissioned providers.
Get the rhythm
- Published:
27 Oct 2016 -
Author:
Martin Hall -
Pages:
40
Diurnal is a clinical stage specialty pharmaceutical company focused on diseases of the endocrine system. It has two lead candidates – Infacort® and Chronocort® – in Phase III trials targeted at rare diseases with unmet medical need with which it aims to build a long-term ‘Adrenal Franchise’. The cortisol replacement market is for conditions that need life-long treatments, with a potential value of $3.5bn. Despite this, the market is characterised by few competitors, and Diurnal will target a network of specialist endocrinology centres in Europe and US by itself. Upcoming newsflow on trials and regulatory filings will draw attention to the stock.